key: cord-0984463-w59zlxmy
authors: Lu, Ligong; Zhang, Hui; Dauphars, Danielle J.; He, You-Wen
title: A Potential Role of Interleukin-10 in COVID-19 Pathogenesis
date: 2020-11-02
journal: Trends Immunol
DOI: 10.1016/j.it.2020.10.012
sha: 70f9e0e2f52307eb1a9e853c817acd3b3c2d6853
doc_id: 984463
cord_uid: w59zlxmy

A unique feature of the cytokine storm in COVID-19 is the dramatic elevation of IL-10. Its significance was thought as a negative-feedback mechanism for suppressing inflammation. However, several lines of clinical evidence suggest that dramatic early pro-inflammatory IL-10 elevation might play a pathological role in COVID-19 severity.

when compared to non-ICU patients [1, 5] . Furthermore, IL-10 concentrations strongly correlated with those of IL-6 and other inflammatory markers such as C-reactive protein [3] . How SARS-CoV-2 infection differs from SARS-CoV in its capacity to stimulate IL-10 expression is currently unknown. However, the importance of IL-10 as a putative immune biomarker in surveying COVID-19 disease severity has emerged. Similar to IL-6, high IL-10 expression can predict poor outcomes in COVID-19 patients [3, 4] . A recent meta-analysis of 1,242 non-severe and 915 severe COVID-19 patients from 18 clinical studies identified IL-6 and IL-10 as covariates that accurately predicted disease severity [7] . Furthermore, IL-10 is elevated earlier than IL-6 in COVID-19 patients [4] . Given the long-recognized pathological role of IL-6 in CRS and the resulting mortality, many clinical trials have been undertaken to test the efficacy of blocking IL-6/IL-6R in potential COVID-19 treatments. In contrast, the clinical significance of highly elevated IL-10 amounts in the serum of COVID-19 patients has been generally regarded as an anti-inflammatory or immune inhibitory mechanism (and hence biomarker), stimulated by the rapid accumulation of proinflammatory cytokines as a negative-feedback loop [4, 5] . Furthermore, recombinant IL-10 has been proposed by some investigator to treat ARDS in COVID-19 patients based on its immune regulatory and anti-fibrotic function [8] . However, several lines of clinical evidence from human studies suggest that the early and dramatic IL-10 elevation upon SARS-CoV-2 infection might instead play a detrimental pathological role in COVID-19 severity. Frequently labeled as an immunosuppressive or anti-inflammatory cytokine, pleiotropic IL-10 can be an immune activating and proinflammatory cytokine in certain autoimmune diseases and cancers in human patients [9] [10] [11] . For example, in a placebocontrolled double blind-study, chronically active Crohn's disease patients treated with recombinant human IL-10 (rIL-10) exhibited enhanced serum production of proinflammatory neopterin, as well as ex vivo PHA-induced IFN- production from whole blood cells [9] , suggesting that IL-10 promotes inflammatory cytokine production in humans. Moreover, administration of pegylated rIL-10 at a high dose (20 g/kg) into advanced solid tumor patients induced systemic immune activation, as evidenced by circulating cytokine production and T lymphocyte activation and proliferation, in addition to exhibiting encouraging clinical efficacy in tumor control [10, 11] . In a phase I, nonrandomized, single group (350 participants), patients with advanced renal cell carcinoma (RCC) treated with rIL-10 alone achieved a 27% overall response (OR) (NCT02009449) II [10] . Furthermore, the combination of rIL-10 and anti-PD-1 antibody treatment of patients with advanced melanoma, RCC and non-small cell lung cancer exhibited an impressive 42% OR (8 out of 42 patients) (NCT02009449 II , NCT03267732 III ) [11] . Three major features of immune activation were observed in these cancer patients. First, rIL-10 induced sustained systemic elevation of inflammatory and immune activating cytokines/mediators, including IL-2R, IL-4, IL-7, IL-18, IFN-GM-CSF, and TNF- in patient serum [10, 11] . Second, rIL-10 stimulated extensive clonal expansion of effector IFN- + CD8 + T cells in both the periphery and tumors of the treated cancer patients [11] . Third, rIL-10 drove peripheral exhausted J o u r n a l P r e -p r o o f Journal Pre-proof patients [1, 3, 4] . Second, severe/critically ill COVID-19 patients bear circulating hyperactivated and proliferating cytotoxic CD8 + T cells despite a total reduction in peripheral CD8 + T-cell count [14] . Furthermore, correlating with high serum IL-10 in severe/critically ill COVID-19 patients, the percentages of IFN- producing effector CD4 + and CD8 + T cells can be increased in peripheral blood [6] . Third, as COVID-19 disease progresses, exhausted PD-1 + TIM-3 + CD8 + T cells in the peripheral blood of patients have been found to increase and correlate with serum IL-10 concentrations in COVID-19 patients, suggesting a role of IL-10 in T cell exhaustion, presumably via overactivation and proliferation [5] . Such immune features in severe/critically ill COVID-19 patients with highly elevated systemic IL-10 have led us to speculate that IL-10 might play a pathological role in COVID-19 disease progression. However, this hypothesis remains to be rigorously tested.

In this scenario, how might elevated IL-10 contribute to COVID-19 mortalityif at all? The immunopathological pathway leading to patient death following SARS-CoV-2 infection can be divided into three stages: initiation, amplification, and consummation [13] . We propose that early induction of IL-10 upon SARS-CoV-2 infection during the initiation phase in the lung might indeed represent a negativefeedback mechanism serving as a countermeasure to inflammation caused by other proinflammatory mediators. However, as endogenous IL-10 production increases, we speculate that it might function as an immune activating/proinflammatory agent that stimulates the production of other mediators of the cytokine storm (Figure 1) . As reported for human endotoxemia [12] , IL-10 might also amplify viral sepsis-related J o u r n a l P r e -p r o o f Journal Pre-proof hyperinflammation observed in some severe/critically ill COVID-19 patients [15] . As IL-10 directly expands cytotoxic effector CD8 + T cells in human studies, hyperactivation of adaptive immunity in COVID-19 patients might contribute to exacerbating disease severity. Although this possibility remains conjectural, we posit that the combined effect of IL-10 on promoting systemic inflammatory cytokine production and stimulating T cell activation and proliferation in COVID-19 patients might contribute to a lethal immunopathological process.

Currently, clinical trials are underway to test the therapeutic efficacy of blocking agents, either alone, or in combination with more than 10 inflammatory mediators reported as highly elevated in COVID-19 patients presenting a cytokine storm (discussed in ref [13] ). Preliminary results from using blocking/neutralizing antibodies against IL-6/IL-6R, GM-CSF, and IL-1 suggest that further improvement is needed to lower mortality in COVID-19 patients [13] . By attempting to block its pathological proinflammatory function, we suggest that IL-10 might constitute a potential target to reduce COVID-19 mortality. As such, the timing for blocking IL-10 activity in severe/critically ill COVID-19 patients might be crucial [13] . We propose that using a neutralizing antibody to block IL-10 to limit its potential immune activating effects in the initiation phase of COVID-19 may be worth testing. Furthermore, we argue that 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVACTA trial raises questions about tocilizumab's benefit in COVID-19

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol 11

The laboratory tests and host immunity of COVID-19 patients with different severity of illness

IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression

Use interleukin-10 as the therapeutic agent for COVID-19

Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8(+) T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

Proinflammatory effects of IL-10 during human endotoxemia

Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm? Front

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

SARS-CoV-2 and viral sepsis: observations and hypotheses

The work is supported by the National Key Research and Development Program of